Drug Search Results
More Filters [+]

Apadenoson

Alternative Names: apadenoson
Latest Update: 2017-02-01
Latest Update Note: Clinical Trial Update

Product Description

Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Apadenoson)

Mechanisms of Action: ADORA2 Agonist

Novel Mechanism: Yes

Modality: Diagnostic Agent

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Apadenoson

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Myocardial Ischemia|Coronary Artery Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASPECT-2

P3

Completed

Coronary Artery Disease

2012-04-18

ASPECT

P3

Terminated

Myocardial Ischemia|Coronary Artery Disease

2012-04-01

ASPECT2

P3

Terminated

Coronary Artery Disease|Myocardial Ischemia

2012-04-01

BMS068645-305

P3

Terminated

Coronary Artery Disease|Myocardial Ischemia

2006-11-01

Recent News Events

Date

Type

Title